PTX 4.44% 4.3¢ prescient therapeutics limited

Interesting to read the response of clinicians regarding the...

  1. 7,810 Posts.
    lightbulb Created with Sketch. 3329
    Interesting to read the response of clinicians regarding the recent FDA review:-

    https://endpts.com/clinicians-say-benefits-of-car-t-continue-to-outweigh-risk-of-t-cell-malignancies/

    In it states the following:-

    The agency has not responded to requests for comment on how many CAR-positive T-cell malignancies were detected and the severity of the cases. Bishop noted that CAR-positive cases do not necessarily mean the patient’s cancer was caused by CAR-T treatment, and more information will be necessary to determine whether patients were predisposed to T-cell lymphomas.

    The fact that T-cell lymphomas is specifically mentioned, bodes extremely well for PTX-100.... the fact that it is a targeted therapy and not a Car-T therapy. Surely, the FDA will be more receptive to our upcoming submission.

 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
4.3¢
Change
-0.002(4.44%)
Mkt cap ! $36.23M
Open High Low Value Volume
4.4¢ 4.4¢ 4.3¢ $5.2K 120.7K

Buyers (Bids)

No. Vol. Price($)
3 320988 4.2¢
 

Sellers (Offers)

Price($) Vol. No.
4.3¢ 51021 3
View Market Depth
Last trade - 12.57pm 25/07/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.